Diamyd Medical AB is a Sweden-based diabetes company. It is active in the field of pharmaceutical development and investments in stem cell and medical technology. The Company develops the diabetes vaccine, Diamyd, with the active glutamic acid decarboxylase (GAD) ingredient for the treatment and prevention of autoimmune diabetes. The vaccine is intended for the treatment of children and adolescents with recent-onset type one diabetes, as well as those at high risk of developing the disease.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-06 Earnings release - Annual 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-11	SEK 1.024	0.00%	287,804
26-08-10	SEK 1.024	+1.39%	246,330
26-08-07	SEK 1.010	-0.39%	188,235
26-08-06	SEK 1.014	-3.06%	198,912
26-08-05	SEK 1.046	+2.35%	182,844

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-08-11 EDT			5-day change	1st Jan Change
1.024 ^SEK	0.00%		+0.20%	-90.91%

07-27	Diamyd Medical CEO buys shares for nearly 100,000 kronor	FW
07-27	Diamyd Medical AB Provides Update On Learnings From DIAGNODE-3 Interim Analysis	CI

Market Cap	159M 16.68M 14.46M 13.53M 12.35M 23.24M 1.59B 23.63M 62.18M 796M 62.64M 61.28M 2.66B	P/E 2026 *	-0.47x	P/E 2027 *	-1.63x
Enterprise Value	5.7M 600K 520K 486K 444K 835K 57.19M 849K 2.23M 28.63M 2.25M 2.2M 95.5M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	75.3%	Yield 2026 *	-	Yield 2027 *	-

07-27	Diamyd Medical CEO buys shares for nearly 100,000 kronor	FW
07-27	Diamyd Medical AB Provides Update On Learnings From DIAGNODE-3 Interim Analysis	CI
07-27	Diamyd points to lessons learned after review of Phase 3 study	FW
06-25	Diamyd Medical Appoints New CFO	MT
06-25	Diamyd Medical names Mathias Skalmstad as new CFO	FW
06-25	Diamyd Medical AB Appoints Mathias Skalmstad as Chief Financial Officer, Effective July 1, 2026	CI
06-24	Diamyd Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI
06-24	Diamyd Medical CEO and major shareholder Anders Essen-Möller increases his stake	FW
06-24	Diamyd Medical reports wider Q3 loss	FW
06-23	Calendar Wednesday June 24	FW
06-23	Diamyd Medical Board to Focus on Strategic Review Following Close-out of Phase 3 Study	MT
06-23	Diamyd Medical signals it may broaden beyond health care after failed Phase 3 trial	FW
06-21	Diamyd Medical AB(OM:DMYD B) dropped from S&P Global BMI Index	CI

03-31	DNB Carnegie slashes Diamyd Medical valuation following trial failure	FW
03-30	DNB Carnegie awaits further clarity from Diamyd Medical - sharp negative share price reaction expected	FW
25-10-09	DNB Carnegie: Strong Finish for Diamyd Medical	FW
25-03-04	Penser temporarily removes fair value for Diamyd Medical due to the rights issue	FW
24-11-22	Penser reiterates fair value for Diamyd Medical after recruitment milestone	FW

Diamyd Medical AB Stock

Stocks

DMYD B

SE0005162880

Biotechnology & Medical Research

Valuation: Diamyd Medical AB

Chart: Diamyd Medical AB

Latest news : Diamyd Medical AB

Last Transcript: Diamyd Medical AB

Analysts' recommendations: Diamyd Medical AB

Press Releases: Diamyd Medical AB

Quotes and Performance

Course Extremes

Managers and Directors: Diamyd Medical AB

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

07-27	Diamyd Medical Provides Update on Learnings from DIAGNODE-3 Interim Analysis	AQ
06-25	Mathias Skalmstad new CFO at Diamyd Medical	AQ
06-24	Diamyd Medical: A difficult reset, but not an empty hand – Q3 2025/26 review	AQ
06-24	Quarterly Report 3 25/26	AQ
06-23	Diamyd Medical provides update on Strategic Review	AQ

1 week	+0.20%
Current month	-0.58%
1 month	-9.70%
3 months	-13.95%
6 months	-93.93%
Current year	-90.91%

1 week	1	1.05
1 month	0.94	1.16
Current year	0.9	17.88
1 year	0.9	17.88
3 years	0.9	25
5 years	0.9	39.84
10 years	0.9	74.7

Manager	Title	Age	Since
Anders Essen-Möller CEO	Chief Executive Officer	85	2026-04-23
Mathias Skalmstad DFI	Director of Finance/CFO	53	2026-06-30
Anton Lindqvist CTO	Chief Tech/Sci/R&D Officer	46	2012-12-31

Director	Title	Age	Since
Anders Essen-Möller CHM	Chairman	85	2023-10-01
Maria-Teresa Essen-Möller BRD	Director/Board Member	56	2008-12-31
Erik Kjellsson Nerpin CHM	Chairman	65	2026-04-23

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/27/25	Anders Essen-Möller	Don	Chief Executive Officer	100,000	0.0791%
5/5/25	Ulf Hannelius	Buy	Chief Executive Officer	1,000	0.0008%
5/2/25	Maja Johansson	Buy		1,020	0.0008%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIAMYD MEDICAL AB	0.00%	+0.20%	-90.94%	-89.05%	16.73M
WUXI APPTEC CO., LTD.	-0.70%	+24.68%	+76.72%	+103.05%	70.85B
ARGENX SE	-2.35%	+2.88%	+35.39%	+64.72%	55.41B
INSMED INCORPORATED	-1.19%	+35.21%	+18.27%	+495.25%	29.43B
WUXI BIOLOGICS (CAYMAN) INC.	-0.30%	+18.51%	+56.61%	+4.86%	24.12B
BIONTECH SE	-0.26%	+1.04%	-15.52%	-13.67%	23.31B
GENMAB A/S	+0.05%	+6.12%	+46.81%	-21.81%	18.37B
PHARMAESSENTIA CORPORATION	+9.77%	+25.32%	+252.40%	+442.16%	16.99B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	0.00%	+10.84%	+31.14%	+628.97%	16.1B
EXELIXIS, INC.	-2.45%	-7.50%	+38.47%	+140.71%	13.12B
Average	+0.26%	+351.74%	+44.94%	+175.52%	26.77B
Weighted average by Cap.	-0.35%	+349.14%	+56.37%	+165.63%

	2026 *	2027 *
Net sales	-	-
Net income	-312M -32.8M -28.42M -26.61M -24.28M -45.69M -3.13B -46.46M -122M -1.57B -123M -120M -5.22B	-95M -9.99M -8.65M -8.1M -7.39M -13.91M -953M -14.15M -37.22M -477M -37.5M -36.68M -1.59B
Net Debt	-153M -16.08M -13.94M -13.05M -11.91M -22.4M -1.53B -22.78M -59.95M -768M -60.39M -59.07M -2.56B	-57M -5.99M -5.19M -4.86M -4.44M -8.35M -572M -8.49M -22.33M -286M -22.5M -22.01M -954M